Literature DB >> 10221231

A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily.

C F Rice1, S R Killick, T Dieben, H Coelingh Bennink.   

Abstract

A randomized, double blind, group comparative study was performed over a 12 month period to compare inhibition of ovulation during the use of two (progestogen-only) oral contraceptives containing doses of 75 micrograms desogestrel or 30 micrograms levonorgestrel. Seventy-one female volunteers with regular cycles and established ovulation by ultrasonography and serum progesterone concentrations were recruited from an out-patient clinic in a university hospital and asked to participate in the study. Transvaginal ultrasonography and serum oestradiol, progesterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) measurements were performed throughout the 7th and 12th 28 day treatment period. Desogestrel at a dose of 75 micrograms showed a significant inhibition of ovulation compared to 30 micrograms levonorgestrel (P < 0.001).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221231     DOI: 10.1093/humrep/14.4.982

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  The sexual health of adolescents with cystic fibrosis.

Authors:  Stephen Roberts; Pippa Green
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

2.  Contraindications to progestin-only oral contraceptive pills among reproductive-aged women.

Authors:  Kari White; Joseph E Potter; Kristine Hopkins; Leticia Fernández; Jon Amastae; Daniel Grossman
Journal:  Contraception       Date:  2012-02-24       Impact factor: 3.375

3.  Oral contraceptives in migraine therapy.

Authors:  Gianni Allais; Ilaria Castagnoli Gabellari; Cristina De Lorenzo; Ornella Mana; Chiara Benedetto
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

4.  Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta.

Authors:  C J Timmer; N Srivastava; T O Dieben; A F Cohen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.569

Review 5.  Recent progress in advanced biomaterials for long-acting reversible contraception.

Authors:  Mingzhe Yan; Yanming Zhang; Zhihang Wu; Yifei Li; Keke Dou; Banghui Wang; Yingruo Wang; Qihui Zhou
Journal:  J Nanobiotechnology       Date:  2022-03-17       Impact factor: 10.435

Review 6.  Contraception and endometriosis: challenges, efficacy, and therapeutic importance.

Authors:  Edith Weisberg; Ian S Fraser
Journal:  Open Access J Contracept       Date:  2015-07-27

Review 7.  The clinical relevance of progestogens in hormonal contraception: Present status and future developments.

Authors:  Pedro-Antonio Regidor
Journal:  Oncotarget       Date:  2018-10-02

Review 8.  Bone health in estrogen-free contraception.

Authors:  P Hadji; E Colli; P-A Regidor
Journal:  Osteoporos Int       Date:  2019-08-24       Impact factor: 4.507

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.